Third Rock Ventures

Third Rock Ventures is a Boston-based biotech firm that pioneered the modern company-creation model in life sciences and has built one of the strongest track records in venture-backed therapeutics. Founded in 2007 by Mark Levin (former CEO of Millennium Pharmaceuticals), Kevin Starr (former COO and CFO of Millennium), Robert Tepper (an MD scientific leader), and Lou Tartaglia (a PhD obesity researcher), Third Rock has invested over $3.8 billion across multiple funds since its founding and has launched more than 60 biotech companies, with notable franchises including Sage Therapeutics, Editas Medicine, Constellation Pharmaceuticals, Flare Therapeutics, Bluebird Bio, Agios Pharmaceuticals, and Foundation Medicine. The firm’s most recent fund closed at $1.1 billion with the explicit plan to create approximately 10 new biotechs.

Third Rock’s distinctive franchise is company creation, not check writing. The firm’s partners actively seek out scientific opportunities, recruit founding teams, build initial business plans, and frequently serve as members of the founding management of newly created companies. This means that Third Rock partners are often listed as founders, interim CEOs, and chairmen of the companies they back, and the firm provides operating capacity, not just capital, to translate academic and clinical insights into investable platforms. Senior partners and managing partners across the firm’s history have included Mark Levin and Kevin Starr (founders), Cary Pfeffer, Neil Exter, Abbie Celniker, Reid Huber, and a deep bench of partners with operating backgrounds at Millennium, Vertex, Genentech, and other biotech operating companies. In 2024 the firm announced the addition of seasoned biotech executives to its senior team to support its expanded company creation activities.

The portfolio reads like a roadmap of validated therapeutic platforms: epigenetics (Constellation, Foundation), cell and gene therapy (Bluebird, Editas), neuroscience (Sage, Tango Therapeutics), oncology (Agios, Flare, Revolution Medicines), rare disease, immunology, RNA therapeutics, and platform biology. Third Rock is one of a small number of firms that has produced multiple platform franchises that scaled from formation through IPO and substantial commercial revenue.

Check sizes are unusually large at formation. Third Rock typically commits $30 million to $100 million across multiple tranches at company formation and Series A, sometimes funding the company’s first three to five years before raising additional capital. The firm leads at formation and Series A and frequently anchors Series B and C as well, working alongside peer specialists including OrbiMed, F-Prime, RA Capital, Versant, and Atlas Venture. Geographic scope is primarily Boston-Cambridge with selective deals across the broader US, particularly in the Bay Area.

Founders who should approach Third Rock are academic principal investigators with breakthrough scientific platforms, repeat biotech entrepreneurs with new therapeutic theses, and clinician-scientists with translational insights that they want to build into a company. The firm is particularly well suited for founders who want a deep operating partner and who are open to a company-creation model where Third Rock partners may serve as interim CEOs or chairmen during the early years. Founders looking for a passive check or a quick term sheet should pitch other firms. Founders building digital health, devices, diagnostics-only, or non-therapeutic businesses are not the right fit; Third Rock is decisively a therapeutics company creation firm.

Entry path runs through academic affiliations, particularly Harvard, MIT, Broad Institute, Whitehead, Dana-Farber, MGH, and the broader Boston-Cambridge research community, plus warm introductions from portfolio CEOs and scientific advisors. Third Rock partners are at JPMorgan Healthcare, BIO, AACR, ASCO, ASH, and the major scientific conferences. Cold inbound through the website is triaged but converts at low rates given the firm’s reliance on its own internal company-creation pipeline.

In a pitch, lead with the science, the unmet need, and the platform thesis. Third Rock partners are deeply technical and operationally experienced; they will probe your scientific differentiation, your IP estate, your translational plan, and your team in detail. Bring rigor and be open to a creation-model partnership where Third Rock contributes operating leadership and capital across multiple years. The firm’s added value is unmatched in the formation and early company-building stages: senior operating talent, scientific advisor networks, manufacturing and CMC expertise, and a track record of building companies that scale from preclinical to commercial. Founders willing to partner deeply with a creation-model firm will find Third Rock Ventures one of the most powerful and unusual tier-one investors in biotech, with the capacity to take an academic insight from formation to IPO under a single partnership relationship.